Major Review Of EU Pharmaceutical Legislation Kicks Off
Roadmap Published As Part Of EU Pharma Strategy
The European Commission has launched the process for reshaping and addressing the long-standing weakness in the EU’s pharmaceutical legislation. It has listed in a roadmap the issues it wants to address as it considers policy options for reforms.
You may also be interested in...
With the EU pharmaceutical legislation due to undergo a radical shake-up to create a future-proof regulatory system, the time is ripe for industry to engage with efforts to make the European drug approval process more agile.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.